Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Pulmonary Arterial Hypertension
- Pulmonary Hypertension
- Type
- Interventional
- Phase
- Not Applicable
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentIntervention Model Description: This is a single-arm, non-randomized early feasibility study to evaluate the feasibility and safety of the Aria CV PH System in patients with pulmonary arterial hypertension.Masking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
This clinical investigation is a prospective, non-randomized, single- arm, multi-center early feasibility study of the Aria CV Pulmonary Hypertension (PH) System implanted in patients with pulmonary arterial hypertension (PAH). The purpose of this study is to validate that the clinical use of the Ar...
This clinical investigation is a prospective, non-randomized, single- arm, multi-center early feasibility study of the Aria CV Pulmonary Hypertension (PH) System implanted in patients with pulmonary arterial hypertension (PAH). The purpose of this study is to validate that the clinical use of the Aria CV PH System is safe for the patient, and to evaluate its performance in treating patients with PAH. The study will be conducted in a maximum of 10 centers in the United States with a planned maximum enrollment of 45 patients to ensure up to 15 "Device Deployed" subjects. Patients will be evaluated at each of the following time intervals: preoperative, implant, 7-day (or discharge if earlier) and 1-, 3-, 6-, 12- and 24-month post index procedure. The Aria CV PH System will be assessed at each follow-up visit, as well as at 2- and 9- month and quarterly between 12 and 24 months. The duration of the study is anticipated to be 2.5 years.
Tracking Information
- NCT #
- NCT04555161
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Aaron Waxman, M.D.,Ph.D. Brigham and Women's Hospital